How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/prevention-of-post-operative-nausea-and-vomiting.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Prevention of Post-Operative Nausea and Vomiting — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevention of Post-Operative Nausea and Vomiting (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Prevention of Post-Operative Nausea and Vomiting, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Emend	APREPITANT	Merck & Co.	Substance P/Neurokinin-1 Receptor Antagonist [EPC]	Substance-P receptor	2003-01-01
Anzemet	DOLASETRON	Validus Pharms	Serotonin-3 Receptor Antagonist	5-hydroxytryptamine receptor 3A	1997-01-01
Zofran	ondansetron	GSK (originally Glaxo)	5-HT3 receptor antagonist (antiemetic)	Aldehyde oxidase, 5-hydroxytryptamine receptor 3B, Multidrug and toxin extrusion protein 1	1991-01-04
Estron	ESTRONE	Watson Labs	estrone	Estrogen receptor	1979-01-01
Reglan	METOCLOPRAMIDE	Hikma	Dopamine-2 Receptor Antagonist	D(3) dopamine receptor	1979-01-01
Reglan	Metoclopramide Hydrochloride	Hikma	Prokinetic agent	Acetylcholine receptor sensitization; dopamine antagonism (implied)	1979-01-01
GRAN®	GRAN®	EVIVE Biotechnology		5-hydroxytryptamine receptor 3B, Multidrug and toxin extrusion protein 1, Solute carrier family 22 member 2
scopolamin	scopolamin	University Hospital, Angers		Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3
Metaclopramide	Metaclopramide	Institute of Liver and Biliary Sciences, India		Aldehyde oxidase, Myeloperoxidase, Solute carrier family 22 member 1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Hikma · 2 drugs in Prevention of Post-Operative Nausea and Vomiting
GSK (originally Glaxo) · 1 drug in Prevention of Post-Operative Nausea and Vomiting
Institute of Liver and Biliary Sciences, India · 1 drug in Prevention of Post-Operative Nausea and Vomiting
Merck & Co. · 1 drug in Prevention of Post-Operative Nausea and Vomiting
University Hospital, Angers · 1 drug in Prevention of Post-Operative Nausea and Vomiting
Validus Pharms · 1 drug in Prevention of Post-Operative Nausea and Vomiting
EVIVE Biotechnology · 1 drug in Prevention of Post-Operative Nausea and Vomiting
Watson Labs · 1 drug in Prevention of Post-Operative Nausea and Vomiting

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Prevention of Post-Operative Nausea and Vomiting:

Cite this brief

Drug Landscape (2026). Prevention of Post-Operative Nausea and Vomiting — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-post-operative-nausea-and-vomiting. Accessed 2026-06-10.

Prevention of Post-Operative Nausea and Vomiting full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing